Fundraising Fox

PepGen

NASDAQ: PEPG

Boston, US · Founded 2020 · 2 known investors

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

JMJames McArthur
James McArthurinChief Executive Officer

Board

RF
Ramin Farzaneh-FarBoard director
JR
Joshua ResnickBoard director
CA
Christopher AshtonBoard director
HH
Heidi HensonBoard director

Investors · 2

Oxford Science EnterprisesOxford · $63.5K – $31.8M
RA CapitalBoston

Funding

SEC filings, press & company announcements

$126.9M disclosed across 2 of 4 rounds · 2020–2025

  • Undisclosed amountpublic offeringSep 2025
    Source ↗
▶$112.5MraisedAug 2021 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ramin Farzaneh-FarDirector
  • Joshua ResnickDirector
  • Christopher AshtonDirector
  • James McArthurExecutive Officer, Director
  • Heidi HensonDirector
Offering amount
$112.5M
Amount sold
$112.5M
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.4MraisedDec 2020 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew WoodDirector
  • Caroline GodfreyExecutive Officer, Director
  • Josh ResnickDirector
  • Ramin Farzaneh-FarDirector
  • Christopher AshtonDirector
Offering amount
$51.8M
Amount sold
$14.4M
First sale
Nov 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS - Ticker Reporttickerreport.com · Aug 2026PepGen reports Q2 loss, holds $117M in cash | PEPG Quarterly Report (10-Q)stocktitan.net · Aug 2026PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA | BioPharma Divebiopharmadive.com · Mar 2026PepGen Raises $115 Million to Advance Oligonucleotide Therapies for Neuromuscular Diseasestrial.medpath.com · Sep 2025PepGen raises $115 million in public offering to fund clinical trials By Investing.cominvesting.com · Sep 2025Therapeutics company PepGen raises $45m Series A funding - The Oxford Magazinetheoxfordmagazine.com · Dec 2020

Frequently asked questions

What does PepGen do?
PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Who are PepGen's investors?
PepGen's investors include Oxford Science Enterprises, RA Capital.
How much funding has PepGen raised?
PepGen has disclosed $126.9M raised across 2 of its 4 known rounds.
Where is PepGen headquartered?
PepGen is headquartered in Boston, US.